@article {Julin2021.08.15.21261478, author = {Cathinka Halle Julin and Anna Hayman Robertson and Olav Hungnes and Gro Tunheim and Terese Bekkevold and Ida Laake and Idunn Forland Aune and Rikard Rykkvin and Dagny Haug Dorenberg and Kathrine Stene-Johansen and Einar Sverre Berg and Johanna Eva Bodin and Fredrik Oftung and Anneke Steens and Lisbeth Meyer N{\ae}ss}, title = {Household transmission of SARS-CoV-2; a prospective longitudinal study showing higher viral load and transmissibility of the Alpha variant compared to previous strains}, elocation-id = {2021.08.15.21261478}, year = {2021}, doi = {10.1101/2021.08.15.21261478}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Objectives We studied the secondary attack rate (SAR), risk factors, and precautionary practices of household transmission in a prospective, longitudinal study. We further compared transmission between the Alpha (B.1.1.7) variant and non-Variant of Concern (non-VOC) viruses.Methods We recruited households of 70 confirmed COVID-19 cases with 146 household contacts from May 2020 to May 2021. Participants donated biological samples 8 times over 6 weeks and answered questionnaires. Whole genome sequencing and droplet digital PCR were used to establish the SARS-CoV-2 variant and viral load.Results SARS-CoV-2 transmission occurred in 60\% of the households, and the overall SAR for household contacts was 50\%. The SAR was significantly higher for the Alpha variant (78\%) compared with non-VOC viruses (43\%) and was associated with a higher viral load. SAR was higher in household contacts aged >=40 years (69\%) than in younger contacts (40-47\%), and for contacts of cases with loss of taste/smell. Children had lower viral loads and were more often asymptomatic than adults. Sleeping separately from the primary case reduced the risk of transmission.Conclusions We found substantial household transmission, particularly for the Alpha variant. Precautionary practices seem to reduce SAR, but preventing household transmission may become difficult with more contagious variants.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Norwegian Institute of Public health.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Regional Committee for Medical and Health Research Ethics (REC), South East Norway B (approval no. 118354). A data protection impact assessment (DPIA) for the study was approved by the data protection officer at the Norwegian Institute of Public Health (NIPH).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are not publicly available}, URL = {https://www.medrxiv.org/content/early/2021/09/22/2021.08.15.21261478}, eprint = {https://www.medrxiv.org/content/early/2021/09/22/2021.08.15.21261478.full.pdf}, journal = {medRxiv} }